Transforming the Treatment of Hypertrophic Cardiomyopathy #AHA2022

Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder, is defined by the presence of increased left ventricular (LV) wall thickness that is not caused by secondary factors. Despite this high prevalence, the majority of individuals with HCM are undiagnosed and untreated. HCM is a disease of the sarcomeres, which are responsible for contraction within cardiac myocytes. Physicians must be able to understand the role of sarcomere dysfunction in the development of HCM and how cardiac myosin inhibitors disrupt these pathological processes.
Supported by an independent educational grant from Cytokinetics.